45.98 0.00 (0.00%)
After hours: 5:11PM EST
|Bid||45.65 x 1100|
|Ask||46.00 x 2900|
|Day's Range||45.94 - 46.39|
|52 Week Range||36.87 - 46.43|
|Beta (5Y Monthly)||0.37|
|PE Ratio (TTM)||46.35|
|Forward Dividend & Yield||1.96 (4.26%)|
|1y Target Est||N/A|
PHILADELPHIA-- -- Expanded indication allows for treatment of women whose advanced ovarian cancer is associated with homologous recombination deficiency Zejula is now the only, once-daily PARP inhibitor approved as monotherapy treatment for recurrent ovarian cancer beyond those with a BRCA mutation in both the recurrent maintenance and late-line treatment settings GlaxoSmithKline today announced that ...
GlaxoSmithKline plc and Innoviva, Inc. today announced the filing of a supplemental New Drug Application to the US Food and Drug Administration seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta , for the treatment of asthma in adults.
The PRIMA study, presented in a Presidential Symposium at the 2019 European Society for Medical Oncology congress and simultaneously published in The New England Journal of Medicine, demonstrates that ...
Data presented at ESMO 2019 support initiation of phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC LONDON , Sept. 28, 2019 /PRNewswire/ -- GlaxoSmithKline plc ...
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector. This approval will give healthcare professionals and people living with severe eosinophilic asthma (SEA) or the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate.
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines. The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.
Expands global footprint for complex API manufacturing WALTHAM, Mass. , May 16, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that ...
Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.